Correction of a release from 02/10/2025, 10:25 CET/CEST - The Platform Group AG raises its forecast for 2026 to EUR 1 billion in sales and EUR 70–80 million in EBITDA – three acquisitions in the pharmaceutical sector and expansion in the Optics & Hearing

About this update from Platform Group Se & Co. Kgaa

EQS-Ad-hoc: The Platform Group AG / Key word(s): Expansion/Change in Forecast Correction of a release from 02/10/2025, 10:25 CET/CEST - The Platform Group AG raises its forecast for 2026 to EUR 1 billion in sales and EUR 70–80 million in EBITDA – three acquisitions in the pharmaceutical sector and expansion in the Optics & Hearing 06-Oct-2025 / 14:00 CET/CEST Correction of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Correction of a release from 02/10/2025, 10:25 CET/CEST – The Platform Group AG raises its forecast for 2026 to EUR 1 billion in sales and EUR  70–80 million in EBITDA – three acquisitions in the pharmaceutical sector and expansion in the Optics & Hearing segment Correction to the second paragraph: The information regarding a shareholding and its legal company name was not presented correctly. The corrected announcement is reproduced in full below. Düsseldorf, 6   October 2025. The Management Board of The Platform Group AG (ISIN: DE000A2QEFA1 ) has decided to raise its medium-term forecast for the 2026 financial year. Net sales of around EUR 1.0 billion (previous forecast: over EUR 860 million) and adjusted EBITDA in a range of EUR 70 million to EUR 80 million (previous forecast: over EUR 64 million) are now expected. Gross merchandise volume (GMV) is expected to rise to around EUR 1.7 billion (previous forecast: EUR 1.6 billion). The forecast for the 2025 financial year remains unchanged. In addition to TPG's positive earnings performance and organic growth, the increase is attributable to the majority acquisition of Cologne-based Apothekia GmbH, which operates a pharmaceutical training platform. In addition, TPG holds a 50% stake in the Vienna-based Contracta Group, which owns 100% of the Austrian company Pharmosan and 79.5% of the Czech company Vamida. Furthermore, further acquisitions in the Optics & Hearing sector are taking place in October. The “Service & Retail Goods” segment will be expanded as a result and will be renamed “Pharma & Service Goods” in the future. The transactions are expected to close by the end of 2025, subject to approval by the relevant antitrust authorities. In addition, The Platform Group has entered into agreements to acquire two further companies in the “Optics & Hearing” segment. Together, these companies generate sales in the single-digit million range with an EBITDA margin of around 24%. Contact: Investor Relations Nathalie Richert Head of Investor Relations [email protected] Schloss Elbroich | Am Falder 4 | 40589 Düsseldorf | Germany corporate.the-platform-group.com End of Inside Information 06-Oct-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com Language: English Company: The Platform Group AG Schloss Elbroich, Am Falder 4 40589 Düsseldorf Germany E-mail: [email protected] Internet: https://the-platform-group.com/ ISIN: DE000A2QEFA1 WKN: A2QEFA Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Oslo EQS News ID: 2208228   End of Announcement EQS News Service 2208228  06-Oct-2025 CET/CEST

View stock analysis, news, and events for Platform Group Se & Co. Kgaa